Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genomics-based drug discovery firm Exelixis has submitted an investigational new drug application to the FDA for its novel anticancer compound, XL820.
Subscribe to our email newsletter
According to the company, this novel small molecule anticancer compound potently inhibits receptor tyrosine kinases (RTKs) implicated in tumor proliferation and vascularization.
XL820 is the fifth compound to advance in clinical development from Exelixis’ internal drug discovery capabilities and represents the first of three anticipated investigational new drug (IND) applications for this year.
In non-clinical studies, XL820 has shown good oral bioavailability and sustained inhibition of target RTKs in vivo following a single oral dose. Pending clearance by the FDA, Exelixis intends to initiate a phase I clinical trial for XL820.
“I am very enthusiastic about the continued productivity of our R&D groups,” said Dr George Scangos, president and CEO of Exelixis. “Before the end of 2005, we anticipate having eight compounds in clinical development, each of which potentially represents an important therapeutic advance.”